No material impact on GSK stock expected. Share Reward Plan acquisitions by PDMRs are routine compensation events, not discretionary insider buying. Monitor upcoming quarterly earnings for fundamental catalysts.
GSK drugs
GSK drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 11 $48.13entry
- T+1 · 2mo ago +3.99%α +4.44% · $50.05
- T+5 · 2mo ago +4.34%α +4.56% · $50.22
- T+20 · 6w ago −3.39%α −5.26% · $46.50
- T+46 · todayOpen
- T+60 · in 20d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
This 6-K filing reports routine acquisitions of GSK ordinary shares by multiple PDMRs (senior executives) under the company's Share Reward Plan on September 9, 2026. Each PDMR acquired 14 shares (7 partnership + 7 matching) at £18.0296 per share. The transactions are plan-based and de minimis in size, representing no material signal for the stock.
Key Facts
- Nine PDMRs (including CFO Julie Brown, President Europe, President Corporate Development, CEO ViiV Healthcare) each acquired 14 ordinary shares under the Share Reward Plan
- All acquisitions executed on September 9, 2026 at £18.0296 per share on the London Stock Exchange
- Each PDMR received 7 partnership shares and 7 matching shares, standard plan structure
- Total shares acquired across all PDMRs: 126 shares (approximately £2,272 aggregate value)
- Transaction type is plan-based, not an open-market discretionary purchase
Financial Impact
De minimis, total consideration approximately £2,272 across all PDMRs at £18.0296/share
Risk Factors
- No material risks identified from this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-008280 |
| Document: 0001654954-26-008280-index-headers.html | 0001654954-26-008280 |
| Document: 0001654954-26-008280-index.html | 0001654954-26-008280 |
| Document: 0001654954-26-008280.txt | 0001654954-26-008280 |
Track record
64 reports on GSK
9 of 18 bullish or bearish reports moved the stock their way by T+20. Best: +9.35% at T+60 after the Jul 17, 2026 report. 15 of 21 went positive at some point.
Filters
- Nov 13, 20263d ago 6-K Neutral 4/10 Entry $50.45 Now $50.41 −0.08% settles Dec 14
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $50.64 Now $50.41 −0.45% settles Dec 11
- Nov 6, 202610d ago 6-K Neutral 1/10 Entry $50.33 Now $50.41 +0.16% settles Dec 7
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $49.13 Now $50.41 +2.61% settles Dec 1
- Oct 28, 202619d ago 6-K Neutral 5/10 Entry $48.74 Now $50.41 +3.43% settles Nov 25
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 1/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 4/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $50.02 Now $50.41 +0.78% settles Nov 18
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers